How Common is 22q11.2 Deletion Syndrome?

22q11.2 deletion syndrome—also known as DiGeorge syndrome or velocardiofacial syndrome (VCFS)—is considered the most common microdeletion syndrome (a genetic condition caused by a tiny missing piece of a chromosome) in humans ^[1][2]. While it is classified as a rare disease, it is more frequent than many people realize. Historically, medical experts estimated that the condition occurs in about 1 in every 2,000 to 1 in 4,000 live births. However, recent data suggests it may be even more common, with the deletion estimated to occur in approximately 1 in every 1,000 pregnancies ^[3]. The vast majority of these cases happen spontaneously (known as de novo mutations), meaning they are not inherited from a parent ^[3].

Why Are Diagnoses Increasing?

In the past, many individuals with 22q11.2 deletion syndrome went undiagnosed or experienced significantly delayed diagnoses. This was often due to a lack of awareness about the syndrome, its wide variety of symptoms (ranging from severe heart defects to mild learning difficulties), and the limitations of older genetic testing methods ^[3]. For older children and adults, it is not uncommon to finally receive a diagnosis years later, after milder symptoms were missed during childhood or attributed to other causes.

Today, the reported rates of 22q11.2 deletion syndrome are steadily increasing, largely due to advancements in medical technology and broader screening practices:

• Advanced Genetic Testing: The widespread use of chromosomal microarray (CMA)—a highly detailed genetic test—allows doctors to detect tiny missing pieces of DNA that older, standard tests (like karyotyping) would completely miss ^[4].
• Better Prenatal Screening: The introduction of non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) has revolutionized prenatal care. This simple blood test taken from the mother during pregnancy can help identify pregnancies at risk for the 22q11.2 deletion ^[5][6]. It is important to note that NIPT is a screening test, not a definitive diagnosis; an “at risk” result always requires confirmation through definitive diagnostic testing, such as amniocentesis or chorionic villus sampling (CVS).
• Targeted Ultrasounds: When routine prenatal ultrasounds detect structural differences, such as a heart defect or an absent thymus (a small organ in the chest important for the immune system), doctors are now much quicker to suspect and formally test for 22q11.2 deletion syndrome ^[7][8].
• Greater General Awareness: As the medical community learns more about the broad spectrum of symptoms—including immune issues, calcium deficiencies, and learning disabilities—doctors are getting better at identifying the syndrome in older children and adults who slipped through the cracks of earlier testing eras.

The Impact of Finding Out Sooner

Detecting the syndrome early—especially before birth—can make a significant difference in a patient’s care. Knowing about a 22q11.2 deletion before a baby is born gives medical teams time to prepare for delivery, leading to better management of the baby’s health ^[9]. For example, the care team can monitor for low blood calcium immediately after birth or prepare for potential neonatal cardiac surgery if a heart defect is present ^[10].

Because modern testing continues to improve, it is likely that the medical community will continue to diagnose 22q11.2 deletion syndrome more accurately and frequently. Whether diagnosed before birth or later in life, an accurate diagnosis provides much-needed answers and ensures individuals get the supportive, tailored care they need.